Table 1.

Summary of Patients Presented According to Response to Etretinate

SID Onset of Chronic GVHD (day postBMT)GVHD Therapy Administered Before EtretinateDuration of cGVHD Before Etretinate (days)Reason for Starting Etretinate Response Duration of Etretinate*Reason for Discontinuation
2  304 Steroids, azathioprine, thalidomide, colchicine  1,046 Progression  Improvement  36 mo (off and on)  Maximal improvement—continued to improve off etretinate  
6  700 Steroids, CSA  215  Failure to improve  Improvement 8.5 mo  GVHD almost completely resolved  
8  279 Steroids, CSA, PUVA  866  Failure to improve Improvement  5 mo  Maximal improvement—continued to improve off etretinate  
11  454  Steroids, CSA  91 Progression  Improvement  Continues  
13  80 Steroids, CSA, thalidomide  1,447  New onset scleroderma Improvement  Continues  
14  397  Steroids, CSA 220  Progression  Improvement  12 mo (until death) Died (COD bacterial pneumonia/liver failure)  
15  180 Steroids, thalidomide, PUVA  1,245  Progression Improvement  Continues  
16  178  Steroids, thalidomide, PUVA, photopheresis  1,019  Progression Improvement  Continues  
17  34  Steroids, azathioprine, thalidomide, PUVA  2,058  Progression Improvement  Continues  
19  724  Steroids, CSA 407  Progression  Improvement  Continues  
20 192  Steroids, CSA  1,044  Progression  Improvement 14 mo  GVHD almost completely resolved  
21  151 Steroids, CSA, thalidomide, FK506  534  Progression Improvement  Continues  
22  85  Steroids, CSA, PUVA  1,861  Progression  Improvement  Continues intermittently  
24  225  Steroids, CSA, PUVA  1,367 Failure to improve  Improvement  Continues  
26 100  Steroids, CSA, azathioprine  2,556  Progression Improvement  Continues  
28  72  Steroids, CSA 1,112  Failure to improve  Improvement  4 mo  Skin breakdown  
29  1,117  Steroids, CSA, PUVA, azathioprine 201  Progression  Improvement  Continues  
30 26  CSA, PUVA, azathioprine  624  New onset scleroderma  Improvement  Continues  
31  454 Steroids, CSA, thalidomide, PUVA  386  Progress Improvement  Continues  
32  306  Steroids, CSA, thalidomide  1,551  Progress  Improvement Continues 
SID  Onset of Chronic GVHD (day postBMT) GVHD Therapy Administered Before Etretinate Duration of cGVHD Before Etretinate (days) Reason for Starting Etretinate  Response  Duration of Etretinate* Reason for Discontinuation  
1  212 Steroids, azathioprine, thalidomide  177  Progression  No response  3.3 mo  Failure to respond and skin peeling  
7 85  Steroids  959  Failure to improve  No response 3 mo  Failure to respond and dry skin, lips, leg ulcers 
10  93  Steroids, CSA, azathioprine, plasmaleukocytopheresis 902  Failure to improve  No response  4 mo  Failure to respond and continued erythematous crusting vesicular lesions on legs  
25  512  Steroids, CSA, azathioprine  461 Progression  No response  10 mo  Failure to respond and skin breakdown  
12  55  Steroids, CSA, thalidomide, PUVA 979  Progression  Progression  6 mo  Progressive sclerosis  
18  305  Steroids  387  Progression Progression  3 mo  Progressive sclerosis  
23  127 Steroids, CSA, PUVA, azathioprine  738  Failure to improve Progression  Unknown  Patient noncompliance  
3 209  Steroids, thalidomide, CSA  834  Progression Nonevaluable  1 d  Patient choice  
4  92 Steroids  354  Progression  Nonevaluable  13 d  Died (COD unknown)  
5  211  Steroids, thalidomide, CSA 1,023  Failure to improve  Nonevaluable  5 d  Died (COD GVHD, Sepsis, Relapse)  
9  197  Steroids, CSA, thalidomide, PUVA  457  Flare of disease  Nonevaluable  2 mo  Died (COD GVHD, aspergillus)  
27  182  Steroids, CSA, thalidomide, azathioprine  1,437  Progression Nonevaluable  1 mo  Skin breakdown 
SID Onset of Chronic GVHD (day postBMT)GVHD Therapy Administered Before EtretinateDuration of cGVHD Before Etretinate (days)Reason for Starting Etretinate Response Duration of Etretinate*Reason for Discontinuation
2  304 Steroids, azathioprine, thalidomide, colchicine  1,046 Progression  Improvement  36 mo (off and on)  Maximal improvement—continued to improve off etretinate  
6  700 Steroids, CSA  215  Failure to improve  Improvement 8.5 mo  GVHD almost completely resolved  
8  279 Steroids, CSA, PUVA  866  Failure to improve Improvement  5 mo  Maximal improvement—continued to improve off etretinate  
11  454  Steroids, CSA  91 Progression  Improvement  Continues  
13  80 Steroids, CSA, thalidomide  1,447  New onset scleroderma Improvement  Continues  
14  397  Steroids, CSA 220  Progression  Improvement  12 mo (until death) Died (COD bacterial pneumonia/liver failure)  
15  180 Steroids, thalidomide, PUVA  1,245  Progression Improvement  Continues  
16  178  Steroids, thalidomide, PUVA, photopheresis  1,019  Progression Improvement  Continues  
17  34  Steroids, azathioprine, thalidomide, PUVA  2,058  Progression Improvement  Continues  
19  724  Steroids, CSA 407  Progression  Improvement  Continues  
20 192  Steroids, CSA  1,044  Progression  Improvement 14 mo  GVHD almost completely resolved  
21  151 Steroids, CSA, thalidomide, FK506  534  Progression Improvement  Continues  
22  85  Steroids, CSA, PUVA  1,861  Progression  Improvement  Continues intermittently  
24  225  Steroids, CSA, PUVA  1,367 Failure to improve  Improvement  Continues  
26 100  Steroids, CSA, azathioprine  2,556  Progression Improvement  Continues  
28  72  Steroids, CSA 1,112  Failure to improve  Improvement  4 mo  Skin breakdown  
29  1,117  Steroids, CSA, PUVA, azathioprine 201  Progression  Improvement  Continues  
30 26  CSA, PUVA, azathioprine  624  New onset scleroderma  Improvement  Continues  
31  454 Steroids, CSA, thalidomide, PUVA  386  Progress Improvement  Continues  
32  306  Steroids, CSA, thalidomide  1,551  Progress  Improvement Continues 
SID  Onset of Chronic GVHD (day postBMT) GVHD Therapy Administered Before Etretinate Duration of cGVHD Before Etretinate (days) Reason for Starting Etretinate  Response  Duration of Etretinate* Reason for Discontinuation  
1  212 Steroids, azathioprine, thalidomide  177  Progression  No response  3.3 mo  Failure to respond and skin peeling  
7 85  Steroids  959  Failure to improve  No response 3 mo  Failure to respond and dry skin, lips, leg ulcers 
10  93  Steroids, CSA, azathioprine, plasmaleukocytopheresis 902  Failure to improve  No response  4 mo  Failure to respond and continued erythematous crusting vesicular lesions on legs  
25  512  Steroids, CSA, azathioprine  461 Progression  No response  10 mo  Failure to respond and skin breakdown  
12  55  Steroids, CSA, thalidomide, PUVA 979  Progression  Progression  6 mo  Progressive sclerosis  
18  305  Steroids  387  Progression Progression  3 mo  Progressive sclerosis  
23  127 Steroids, CSA, PUVA, azathioprine  738  Failure to improve Progression  Unknown  Patient noncompliance  
3 209  Steroids, thalidomide, CSA  834  Progression Nonevaluable  1 d  Patient choice  
4  92 Steroids  354  Progression  Nonevaluable  13 d  Died (COD unknown)  
5  211  Steroids, thalidomide, CSA 1,023  Failure to improve  Nonevaluable  5 d  Died (COD GVHD, Sepsis, Relapse)  
9  197  Steroids, CSA, thalidomide, PUVA  457  Flare of disease  Nonevaluable  2 mo  Died (COD GVHD, aspergillus)  
27  182  Steroids, CSA, thalidomide, azathioprine  1,437  Progression Nonevaluable  1 mo  Skin breakdown 

Abbreviation: SID, subject identifier, assigned chronologically according to the date of starting etretinate.

*

Patients tolerating therapy and who are responding continue etretinate until maximal response. No maximal duration of therapy has been defined.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal